CIK 0001737953
- Non-accelerated filer
- Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822082553
- Phone
- +1 781-222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- 4 Grant or award Chief Medical Officer acquired 20,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 46,035 shares (grant or award)
- 4 Grant or award President & Chief R&D Officer acquired 76,865 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 85,415 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 39,285 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Operating Officer sold 30,000 shares at an average $33.54 ($1,006,106)
- 4 Open-market sale Chief Operating Officer sold 30,000 shares at an average $36.32 ($1,089,537)
- 4 Open-market sale 10% owner sold 5,249 shares at $45.00 ($236,205)
- 4 Open-market sale Director sold 5,558 shares at $46.14 ($256,446)
- 4 Open-market sale Director sold 30,350 shares at an average $45.42 ($1,378,444)
- 4 Open-market sale President & Chief R&D Officer sold 60,000 shares at an average $44.43 ($2,665,973)
Page 10 of 16 · 316 filings